Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Average PT from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $4.79.

MRNS has been the topic of a number of recent research reports. StockNews.com began coverage on shares of Marinus Pharmaceuticals in a research note on Monday. They set a “sell” rating on the stock. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th.

Marinus Pharmaceuticals Price Performance

NASDAQ MRNS opened at $0.54 on Wednesday. The stock has a market capitalization of $29.65 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50. The business has a 50 day simple moving average of $0.35 and a two-hundred day simple moving average of $1.01.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth approximately $727,000. Acadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth $813,000. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $206,000. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the period. Finally, Point72 DIFC Ltd bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth $28,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.